search
Back to results

Determinants of Diabetes Remission After Gastric Bypass Surgery

Primary Purpose

Type 2 Diabetes Mellitus

Status
Completed
Phase
Early Phase 1
Locations
United States
Study Type
Interventional
Intervention
Exendin9
Sponsored by
Blandine Laferrere
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Type 2 Diabetes Mellitus focused on measuring Type 2 Diabetes Mellitus, Gastric Bypass Surgery, Exendin9

Eligibility Criteria

18 Years - 65 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Patients with a wide range of T2DM (duration, treatment modalities and control, in or not in remission) and scheduled for GBP surgery
  • Blood pressure is under at least moderate control <160/100 mmHg
  • Patients can be on dyslipidemia medications but need fasting triglyceride < 600 mg/dl
  • Patients without recent (last 6 months) history of cardiovascular disease (CVD)
  • BMI > 35 and < 55 kg/m2 prior to GBP surgery

Exclusion Criteria:

  • Active cancer
  • Unstable angina
  • Recent stroke
  • Current therapy that may affect glucose metabolism such as glucocorticoids, HIV medications, etc
  • Active infection
  • Kidney failure
  • Severe liver dysfunction
  • Severe respiratory or cardiac failure
  • History of allergic reaction to exendin 9-39
  • History of pancreatitis, history of cholelithiasis, history of alcoholism
  • Presence of high triglyceride levels (>600 ng/dl)
  • Pregnancy (a pregnancy test will be done prior to enrollment and prior to each procedure in all premenopausal women)

Sites / Locations

  • New York Obesity Research Center, Columbia University

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Exendin9

Arm Description

Longitudinal study of insulin secretion and sensitivity in patients with type 2 diabetes before and after gastric bypass surgery.

Outcomes

Primary Outcome Measures

Beta Cell Sensitivity (BCS)
Oral glucose tolerance test (OGTT) will be used to calculate BCS Graded glucose infusion with arginine (GGI) will be used to calculate BCS

Secondary Outcome Measures

Insulin Secretion Rate (ISR) after OGTT
An oral glucose tolerance test (OGTT) will be used to estimate ISR in subjects before and up to 2 years after GBP
Insulin Secretion Rate (ISR) after GGI
A graded glucose infusion with arginine (GGI) will be used to estimate ISR in subjects before and up to 2 years after GBP
Maximal Beta Cell Function
The effect of a graded glucose infusion with arginine (GGI) on insulin secretion rate (ISR) will be measured in subjects before and up to 2 years after GBP

Full Information

First Posted
October 10, 2014
Last Updated
April 21, 2020
Sponsor
Blandine Laferrere
Collaborators
National Institutes of Health (NIH), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
search

1. Study Identification

Unique Protocol Identification Number
NCT02287285
Brief Title
Determinants of Diabetes Remission After Gastric Bypass Surgery
Official Title
Long Term Change of GLP-1 Insulinotropic Effect After GBP Surgery
Study Type
Interventional

2. Study Status

Record Verification Date
April 2020
Overall Recruitment Status
Completed
Study Start Date
October 2014 (Actual)
Primary Completion Date
August 2017 (Actual)
Study Completion Date
July 2019 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor-Investigator
Name of the Sponsor
Blandine Laferrere
Collaborators
National Institutes of Health (NIH), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Longitudinal study of beta cell function up to 2 years after GBP surgery. Evaluation of the role of endogenous glucagon-like peptide-1 (GLP-1).
Detailed Description
The increased prevalence of obesity and type 2 diabetes (T2DM) has resulted in a surge in the number of patients seeking surgical weight loss. Gastric bypass surgery (GBP) results in 30-40% body weight loss with resolution of T2DM in 40-80% of cases. The mechanisms by which T2DM improves after GBP are unclear. Glycemic control occurs long before significant weight loss, suggesting that the nature of the procedure, rather than the weight loss, is responsible for the T2DM improvement. Recent data have singled out the role of the gut hormones known as incretins in diabetes improvement after GBP. The current proposal will study 1) whether the short and long term change in the gut hormone incretins after GBP results in improved insulin secretion in response to the administration of oral and IV glucose, in patients with diabetes undergoing GBP surgery; 2) the factors responsible for diabetes remission - or lack of - after GBP. The investigators wish to apply our finding to define better surgical outcome on diabetes.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Type 2 Diabetes Mellitus
Keywords
Type 2 Diabetes Mellitus, Gastric Bypass Surgery, Exendin9

7. Study Design

Primary Purpose
Treatment
Study Phase
Early Phase 1
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
25 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Exendin9
Arm Type
Experimental
Arm Description
Longitudinal study of insulin secretion and sensitivity in patients with type 2 diabetes before and after gastric bypass surgery.
Intervention Type
Drug
Intervention Name(s)
Exendin9
Other Intervention Name(s)
Exendin(9-39)
Intervention Description
Dosed at 600 pmol/kg/min for 210 minutes.
Primary Outcome Measure Information:
Title
Beta Cell Sensitivity (BCS)
Description
Oral glucose tolerance test (OGTT) will be used to calculate BCS Graded glucose infusion with arginine (GGI) will be used to calculate BCS
Time Frame
at 2 years post GBP surgery
Secondary Outcome Measure Information:
Title
Insulin Secretion Rate (ISR) after OGTT
Description
An oral glucose tolerance test (OGTT) will be used to estimate ISR in subjects before and up to 2 years after GBP
Time Frame
2 years post GBP surgery
Title
Insulin Secretion Rate (ISR) after GGI
Description
A graded glucose infusion with arginine (GGI) will be used to estimate ISR in subjects before and up to 2 years after GBP
Time Frame
2 years post GBP surgery
Title
Maximal Beta Cell Function
Description
The effect of a graded glucose infusion with arginine (GGI) on insulin secretion rate (ISR) will be measured in subjects before and up to 2 years after GBP
Time Frame
2 years post GBP surgery

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Patients with a wide range of T2DM (duration, treatment modalities and control, in or not in remission) and scheduled for GBP surgery Blood pressure is under at least moderate control <160/100 mmHg Patients can be on dyslipidemia medications but need fasting triglyceride < 600 mg/dl Patients without recent (last 6 months) history of cardiovascular disease (CVD) BMI > 35 and < 55 kg/m2 prior to GBP surgery Exclusion Criteria: Active cancer Unstable angina Recent stroke Current therapy that may affect glucose metabolism such as glucocorticoids, HIV medications, etc Active infection Kidney failure Severe liver dysfunction Severe respiratory or cardiac failure History of allergic reaction to exendin 9-39 History of pancreatitis, history of cholelithiasis, history of alcoholism Presence of high triglyceride levels (>600 ng/dl) Pregnancy (a pregnancy test will be done prior to enrollment and prior to each procedure in all premenopausal women)
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Blandine Laferrere, MD
Organizational Affiliation
New York Obesity Nutrition Research Center, Columbia University
Official's Role
Principal Investigator
Facility Information:
Facility Name
New York Obesity Research Center, Columbia University
City
New York
State/Province
New York
ZIP/Postal Code
10032
Country
United States

12. IPD Sharing Statement

Plan to Share IPD
Yes
IPD Sharing Plan Description
The data generated from this study will be presented at national or international conferences and published in a timely fashion. All final peer-reviewed manuscripts that arise from this study will be submitted upon acceptance for publication to the digital archive NIH National Library of Medicine PubMed Central (PMC) database, according to the NIH Policy on Enhancing Public Access to Archived Publications Resulting from NIH Funded Research. Any data released for publication will be for research purposes only and will not include identifiable data on any of the participants.
IPD Sharing Time Frame
Wherever applicable, fully de-identified data will be deposited to appropriate public repositories, following the Federal Health Insurance Privacy and Portability Act (HIPAA). This will occur no longer than 6 months after publications of the data generated by this record, or, 18 months after completion of the funding period, should no data had been published..
IPD Sharing Access Criteria
contact the PI
Citations:
PubMed Identifier
34857533
Citation
Prasad M, Mark V, Ligon C, Dutia R, Nair N, Shah A, Laferrere B. Role of the Gut in the Temporal Changes of beta-Cell Function After Gastric Bypass in Individuals With and Without Diabetes Remission. Diabetes Care. 2022 Feb 1;45(2):469-476. doi: 10.2337/dc21-1270.
Results Reference
derived
PubMed Identifier
30523032
Citation
Shah A, Holter MM, Rimawi F, Mark V, Dutia R, McGinty J, Levin B, Laferrere B. Insulin Clearance After Oral and Intravenous Glucose Following Gastric Bypass and Gastric Banding Weight Loss. Diabetes Care. 2019 Feb;42(2):311-317. doi: 10.2337/dc18-1036. Epub 2018 Dec 6.
Results Reference
derived

Learn more about this trial

Determinants of Diabetes Remission After Gastric Bypass Surgery

We'll reach out to this number within 24 hrs